| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.4M | -20.6% | -34.4% |
| SG&A Expense | $1.9M | +20.8% | +30.8% |
| Operating Income | -$4.3M | +6.5% | +16.0% |
| Net Income | -$4.2M | +3.5% | +7.3% |
| EPS (Basic) | -$0.39 | +2.5% | +7.1% |
| EPS (Diluted) | -$0.39 | +2.5% | +7.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $8.4M | +38.4% | +3.5% |
| Short-term Investments | $4.0M | -59.6% | -80.1% |
| Current Assets | $13.5M | -21.7% | -55.0% |
| Total Assets | $13.6M | -21.8% | -55.0% |
| Current Liabilities | $4.0M | -17.3% | +12.2% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$12.9M | — | — |
| Capital Expenditures | $2K | — | — |
| Investing Cash Flow | $12.8M | — | — |
| Financing Cash Flow | $972K | — | — |
| Free Cash Flow | -$12.9M | — | — |
| $4.0M |
| -17.5% |
| +9.3% |
| Stockholders' Equity | $9.6M | -23.4% | -64.0% |